Reiffel JA - Search Results

1

A consensus report on antiarrhythmic drug use.

Reiffel JA, Estes NA 3rd, Waldo AL, Prystowsky EN, DiBianco R. Reiffel JA, et al. Clin Cardiol. 1994 Mar;17(3):103-16. doi: 10.1002/clc.4960170303. Clin Cardiol. 1994. PMID: 8168278 Free article. Review.

2

Physician attitudes toward the use of type IC antiarrhythmics after the Cardiac Arrhythmia Suppression Trial (CAST).

Reiffel JA, Cook JR. Reiffel JA, et al. Am J Cardiol. 1990 Nov 15;66(17):1262-4. doi: 10.1016/0002-9149(90)91115-m. Am J Cardiol. 1990. PMID: 2122707 Free article. No abstract available.

3

How do physicians determine when to perform an "on-drug" electrophysiology study for efficacy determination in patients with sustained ventricular tachyarrhythmias: a previously unaddressed variable that may affect efficacy rates.

Reiffel JA, Banker J. Reiffel JA, et al. Pacing Clin Electrophysiol. 1995 Mar;18(3 Pt 1):406-16. doi: 10.1111/j.1540-8159.1995.tb02539.x. Pacing Clin Electrophysiol. 1995. PMID: 7770360

4

Structural heart disease: its importance in association with antiarrhythmic drug therapy.

Reiffel JA, Correia J. Reiffel JA, et al. Clin Cardiol. 1994 Sep;17(9 Suppl 2):II3-6. doi: 10.1002/clc.4960171404. Clin Cardiol. 1994. PMID: 7882611 Free article. Review.

5

Influence of Holter monitor and electrophysiologic study methods and efficacy criteria on the outcome of patients with ventricular tachycardia and ventricular fibrillation in the ESVEM trial.

Reiffel JA, Reiter MJ, Freedman RA, Mann D, Huang SK, Hahn E, Hartz V, Mason J; ESVEM Investigators. Reiffel JA, et al. Prog Cardiovasc Dis. 1996 Mar-Apr;38(5):359-70. doi: 10.1016/s0033-0620(96)80029-6. Prog Cardiovasc Dis. 1996. PMID: 8604440 Free article. Clinical Trial.

6

Implications of the Electrophysiologic Study versus Electrocardiographic Monitoring trial for controlling ventricular tachycardia and fibrillation.

Reiffel JA. Reiffel JA. Am J Cardiol. 1996 Aug 29;78(4A):34-40. doi: 10.1016/s0002-9149(96)00451-1. Am J Cardiol. 1996. PMID: 8780327 Free article.

7

Effects of the ventricular activation sequence on the JT interval.

Banker J, Dizon J, Reiffel J. Banker J, et al. Am J Cardiol. 1997 Mar 15;79(6):816-9. doi: 10.1016/s0002-9149(97)89276-4. Am J Cardiol. 1997. PMID: 9070571 Free article.

8

Sotalol for ventricular tachyarrhythmias: beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure. ESVEM Investigators. Electrophysiologic Study Versus Electrocardiographic Monitoring.

Reiffel JA, Hahn E, Hartz V, Reiter MJ. Reiffel JA, et al. Am J Cardiol. 1997 Apr 15;79(8):1048-53. doi: 10.1016/s0002-9149(97)00045-3. Am J Cardiol. 1997. PMID: 9114762 Clinical Trial.

9

Prolonging survival by reducing arrhythmic death: pharmacologic therapy of ventricular tachycardia and fibrillation.

Reiffel JA. Reiffel JA. Am J Cardiol. 1997 Oct 23;80(8A):45G-55G. doi: 10.1016/s0002-9149(97)00713-3. Am J Cardiol. 1997. PMID: 9354411 Free article. Review.

10

Impact of structural heart disease on the selection of class III antiarrhythmics for the prevention of atrial fibrillation and flutter.

Reiffel JA. Reiffel JA. Am Heart J. 1998 Apr;135(4):551-6. doi: 10.1016/s0002-8703(98)70266-2. Am Heart J. 1998. PMID: 9539466 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

292 results

Search Page

Filters